ABBV AbbVie Inc
Price (delayed)
$202.08
Market cap
$356.74B
P/E Ratio
84.2
Dividend/share
$6.29
EPS
$2.4
Enterprise value
$418.36B
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate
Highlights
ABBV's gross profit is up by 16% year-on-year and by 6% since the previous quarter
The gross margin has grown by 12% YoY and by 4.2% from the previous quarter
The debt rose by 13% year-on-year but it has declined by 6% since the previous quarter
ABBV's P/E is 137% above its 5-year quarterly average of 35.6 and 33% above its last 4 quarters average of 63.5
AbbVie's equity has plunged by 68% YoY and by 45% from the previous quarter
Key stats
What are the main financial stats of ABBV
Market
Valuations
Earnings
Shares outstanding
1.77B
Market cap
$356.74B
Enterprise value
$418.36B
Price to earnings (P/E)
84.2
Price to book (P/B)
107.4
Price to sales (P/S)
6.35
EV/EBIT
71.3
EV/EBITDA
29.35
EV/Sales
7.43
Revenue
$56.33B
Gross profit
$39.43B
Operating income
$9.14B
Net income
$4.28B
EBIT
$5.87B
EBITDA
$14.25B
Free cash flow
$17.83B
Per share
Balance sheet
Liquidity
EPS
$2.4
EPS diluted
$2.39
Free cash flow per share
$10.08
Book value per share
$1.88
Revenue per share
$31.85
TBVPS
$22.69
Total assets
$135.16B
Total liabilities
$131.8B
Debt
$67.14B
Equity
$3.33B
Working capital
-$13.17B
Debt to equity
20.19
Current ratio
0.66
Quick ratio
0.43
Net debt/EBITDA
4.32
Margins
Efficiency
Dividend
EBITDA margin
25.3%
Gross margin
70%
Net margin
7.6%
Operating margin
16.2%
Return on assets
3%
Return on equity
70.9%
Return on invested capital
9.1%
Return on capital employed
6.1%
Return on sales
10.4%
Dividend yield
3.11%
DPS
$6.29
Payout ratio
262.1%
ABBV stock price
How has the AbbVie stock price performed over time
Intraday
0.6%
1 week
4.78%
1 month
17.07%
1 year
15.38%
YTD
13.72%
QTD
13.72%
Financial performance
How have AbbVie's revenue and profit performed over time
Revenue
$56.33B
Gross profit
$39.43B
Operating income
$9.14B
Net income
$4.28B
Gross margin
70%
Net margin
7.6%
The operating margin has declined by 35% since the previous quarter and by 31% year-on-year
The operating income has contracted by 34% from the previous quarter and by 28% YoY
The net margin has declined by 17% since the previous quarter and by 16% year-on-year
ABBV's gross profit is up by 16% year-on-year and by 6% since the previous quarter
Growth
What is AbbVie's growth rate over time
Valuation
What is AbbVie stock price valuation
P/E
84.2
P/B
107.4
P/S
6.35
EV/EBIT
71.3
EV/EBITDA
29.35
EV/Sales
7.43
ABBV's P/E is 137% above its 5-year quarterly average of 35.6 and 33% above its last 4 quarters average of 63.5
The EPS has contracted by 17% from the previous quarter and by 12% YoY
ABBV's price to book (P/B) is 81% higher than its last 4 quarters average of 59.3
AbbVie's equity has plunged by 68% YoY and by 45% from the previous quarter
ABBV's P/S is 38% above its 5-year quarterly average of 4.6 and 9% above its last 4 quarters average of 5.8
ABBV's revenue is up by 3.7% year-on-year
Efficiency
How efficient is AbbVie business performance
The ROE has soared by 77% YoY and by 8% from the previous quarter
AbbVie's ROIC has decreased by 38% from the previous quarter and by 31% YoY
The ROS has contracted by 37% from the previous quarter and by 29% YoY
AbbVie's return on assets has decreased by 17% QoQ and by 17% YoY
Dividends
What is ABBV's dividend history
DPS
$6.29
Dividend yield
3.11%
Payout ratio
262.1%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did AbbVie financials performed over time
AbbVie's total assets is 2.6% higher than its total liabilities
The quick ratio has contracted by 32% YoY and by 2.3% from the previous quarter
ABBV's current ratio is down by 24% year-on-year
The company's debt to equity has surged by 71% QoQ
AbbVie's equity has plunged by 68% YoY and by 45% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.